Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives

References

• JennetteJCFalkRJBaconPA2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitidesArthritis Rheumatol2013651111
   PubMed Web of Science ®Google Scholar
• MahrAKatsahianSVaretHRevisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysisAnn Rheum Dis20137261003101022962314
   PubMed Web of Science ®Google Scholar
• MukhtyarCFlossmannOHellmichBOutcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task forceAnn Rheum Dis20086771004101017911225
   PubMed Web of Science ®Google Scholar
• BeidlemanBWegener’s granulomatosis: prolonged therapy with large doses of steroidsJAMA1963186982783014061063
   PubMed Web of Science ®Google Scholar
• FauciASWolffSMJohnsonJSEffect of cyclophosphamide upon the immune response in Wegener’s granulomatosisN Engl J Med197128527149314965127139
   PubMed Web of Science ®Google Scholar
• JonesRBTervaertJWHauserTRituximab versus cyclophosphamide in ANCA-associated renal vasculitisN Engl J Med2010363321122020647198
   PubMed Web of Science ®Google Scholar
• StoneJHMerkelPASpieraRRituximab versus cyclophosphamide for ANCA-associated vasculitisN Engl J Med2010363322123220647199
   PubMed Web of Science ®Google Scholar
• LeeSSAduDThompsonRAAnti-myeloperoxidase antibodies in systemic vasculitisClin Exp Immunol199079141462154347
   PubMed Web of Science ®Google Scholar
• van der WoudeFJRasmussenNLobattoSAutoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosisLancet1985184264254292857806
   PubMed Web of Science ®Google Scholar
• LüdemannJUtechtBGrossWLAnti-neutrophil cytoplasm antibodies in Wegener’s granulomatosis recognize an elastinolytic enzymeJ Exp Med199017113573621688612
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJPathogenesis of antineutrophil cytoplasmic autoantibody-mediated diseaseNat Rev Rheumatol201410846347325003769
   PubMed Web of Science ®Google Scholar
• FalkRJTerrellRSCharlesLAJennetteJCAnti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitroProc Natl Acad Sci U S A19908711411541192161532
   PubMed Web of Science ®Google Scholar
• HuugenDXiaoHvan EschAAggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-αAm J Pathol20051671475815972951
   PubMed Web of Science ®Google Scholar
• SchreiberAXiaoHJennetteJCSchneiderWLuftFCKettritzRC5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritisJ Am Soc Nephrol200920228929819073822
   PubMed Web of Science ®Google Scholar
• KessenbrockKKrumbholzMSchönermarckUNetting neutrophils in autoimmune small-vessel vasculitisNat Med200915662362519448636
   PubMed Web of Science ®Google Scholar
• EwertBHJennetteJCFalkRJAnti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cellsKidney Int19924123753831313124
   PubMed Web of Science ®Google Scholar
• SavageCOGaskinGPuseyCDPearsonJDMyeloperoxidase binds to vascular endothelial cells, is recognized by ANCA and can enhance complement dependent cytotoxicityAdv Exp Med Biol19933361211238296599
   PubMedGoogle Scholar
• XiaoHHeeringaPHuPAntineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in miceJ Clin Invest2002110795596312370273
   PubMed Web of Science ®Google Scholar
• BansalPJTobinMCNeonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvementAnn Allergy Asthma Immunol200493439840115521377
   PubMed Web of Science ®Google Scholar
• MartinFChanACPathogenic roles of B cells in human autoimmunity: insights from the clinicImmunity200420551752715142521
   PubMed Web of Science ®Google Scholar
• VoswinkelJMüllerALamprechtPIs PR3-ANCA formation initiated in Wegener’s granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody productionAnn N Y Acad Sci20051051121916126940
   PubMed Web of Science ®Google Scholar
• VoswinkelJMuellerAKraemerJAB lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesionsAnn Rheum Dis200665785986416291812
   PubMed Web of Science ®Google Scholar
• KrumbholzMSpecksUWickMKalledSLJenneDMeinlEBAFF is elevated in serum of patients with Wegener’s granulomatosisJ Autoimmun200525429830216242914
   PubMed Web of Science ®Google Scholar
• SandersJSHuitmaMGKallenbergCGStegemanCAPlasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapseAnn Rheum Dis200665111484148916504995
   PubMed Web of Science ®Google Scholar
• NagaiMHirayamaKEbiharaIShimohataHKobayashiMKoyamaASerum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activityNephron Clin Pract20111184c339c34521293157
   PubMedGoogle Scholar
• ScapiniPBazzoniFCassatellaMARegulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophilsImmunol Lett200811611618155301
   PubMed Web of Science ®Google Scholar
• TedderTFEngelPCD20: a regulator of cell-cycle progression of B lymphocytesImmunol Today19941594504547524522
   PubMedGoogle Scholar
• WeinerGJRituximab: mechanism of actionSemin Hematol201047211512320350658
   PubMed Web of Science ®Google Scholar
• StoryCMMikulskaJESimisterNEA major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetusJ Exp Med19941806237723817964511
   PubMed Web of Science ®Google Scholar
• KuoTTAvesonVGNeonatal Fc receptor and IgG-based therapeuticsMAbs20113542243022048693
   PubMed Web of Science ®Google Scholar
• GhetieVHubbardJGKimJKTsenMFLeeYWardESAbnormally short serum half-lives of IgG in β2-microglobulin-deficient miceEur J Immunol19962636906968605939
   PubMed Web of Science ®Google Scholar
• IsraelEJWilskerDFHayesKCSchoenfeldDSimisterNEIncreased clearance of IgG in mice that lack β2-microglobulin:possible protective role of FcRnImmunology19968945735789014824
   PubMed Web of Science ®Google Scholar
• DostalekMGardnerIGurbaxaniBMRoseRHChettyMPharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodiesClin Pharmacokinet20135228312423299465
   PubMed Web of Science ®Google Scholar
• GolayJSemenzatoGRambaldiALessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsMAbs20135682683723933992
   PubMed Web of Science ®Google Scholar
• RegazziMBIaconaIAvanziniMAPharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settingsTher Drug Monit200527678579216306856
   PubMed Web of Science ®Google Scholar
• BeersSAFrenchRRChanHTAntigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selectionBlood2010115255191520120223920
   PubMed Web of Science ®Google Scholar
• VaughanATIriyamaCBeersSAInhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificityBlood2014123566967724227819
   PubMed Web of Science ®Google Scholar
• ReddyVCambridgeGIsenbergDAGlennieMJCraggMSLeandroMInternalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosusArthritis Rheumatol20156782046205525916583
   PubMed Web of Science ®Google Scholar
• BeumPVPeekEMLindorferMALoss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cellsJ Immunol201118763438344721841127
   PubMed Web of Science ®Google Scholar
• MullerCMurawskiNWiesenMHThe role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLBlood2012119143276328422337718
   PubMed Web of Science ®Google Scholar
• JägerUFridrikMZeitlingerMRituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseHaematologica20129791431143822511498
   PubMed Web of Science ®Google Scholar
• CarellaAMde SouzaCALuminariSPrognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyLeuk Lymphoma2013541535722712840
   PubMed Web of Science ®Google Scholar
• WengWKLevyRTwo immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphomaJ Clin Oncol200321213940394712975461
   PubMed Web of Science ®Google Scholar
• BerinsteinNLGrillo-LópezAJWhiteCAAssociation of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphomaAnn Oncol19989999510019818074
   PubMed Web of Science ®Google Scholar
• LiJZhiJWengerMPopulation pharmacokinetics of rituximab in patients with chronic lymphocytic leukemiaJ Clin Pharmacol201252121918192622235140
   PubMed Web of Science ®Google Scholar
• NgCMBrunoRCombsDDaviesBPopulation pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trialJ Clin Pharmacol200545779280115951469
   PubMed Web of Science ®Google Scholar
• PuissetFWhite-KoningMKamarNPopulation pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated diseaseBr J Clin Pharmacol201376573474023432476
   PubMed Web of Science ®Google Scholar
• VieiraCAAgarwalABookBKRituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokineticsTransplantation200477454254815084932
   PubMed Web of Science ®Google Scholar
• BarcelliniWZajaFZaninoniALow-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studiesBlood2012119163691369722267606
   PubMed Web of Science ®Google Scholar
• BlumSGillisDBrownHUse and monitoring of low dose rituximab in myasthenia gravisJ Neurol Neurosurg Psychiatry201182665966321071753
   PubMed Web of Science ®Google Scholar
• VisentiniMGranataMVenezianoMLEfficacy of low-dose rituximab for mixed cryoglobulinemiaClin Immunol20071251303317692572
   PubMed Web of Science ®Google Scholar
• Galarza-MaldonadoCKourilovitchMRMolinerosJEThe administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosusAutoimmun Rev201010210811120804861
   PubMed Web of Science ®Google Scholar
• HorváthBHuizingaJPasHHMulderABJonkmanMFLow-dose rituximab is effective in pemphigusBr J Dermatol2012166240541221967609
   PubMed Web of Science ®Google Scholar
• MoogPProbstMKuechleCHauserCHeemannUThuermelKSingle-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patientsScand J Rheumatol201443651952325179776
   PubMed Web of Science ®Google Scholar
• Turner-StokesTSandhuEPepperRJInduction treatment of ANCA-associated vasculitis with a single dose of rituximabRheumatology (Oxford)20145381395140324609057
   PubMed Web of Science ®Google Scholar
• SpecksUFervenzaFCMcDonaldTJHoganMCResponse of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapyArthritis Rheumatol2001441228362840
   PubMed Web of Science ®Google Scholar
• JonesRBFerraroAJChaudhryANA multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheumatol200960721562168
   PubMed Web of Science ®Google Scholar
• SeoPSpecksUKeoghKAEfficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestationsJ Rheumatol200835102017202318688911
   PubMed Web of Science ®Google Scholar
• Cartin-CebaRGolbinJMKeoghKARituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single centerArthritis Rheumatol2012641137703778
   PubMedGoogle Scholar
• HolleJUDubrauCHerlynKRituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestationsAnn Rheum Dis201271332733322021864
   PubMed Web of Science ®Google Scholar
• Martinez Del PeroMChaudhryAJonesRBSivasothyPJaniPJayneDB-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort studyClin Otolaryngol200934432833519673980
   PubMed Web of Science ®Google Scholar
• PulleritsRLjevakMVikgrenJBokarewaMOff-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centreScand J Immunol201276441142022823472
   PubMed Web of Science ®Google Scholar
• CharlesPNeelATieulieNRituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multi-centre retrospective study on 80 patientsRheumatology201453353253924282319
   PubMed Web of Science ®Google Scholar
• MohammadAJHotAArndtFRituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)Ann Rheum Dis Epub2014122
   Web of Science ®Google Scholar
• MuñozSAGandinoIJOrdenAOAllieviARituximab in the treatment of eosinophilic granulomatosis with polyangiitisReumatol Clin201511316516925523986
   PubMedGoogle Scholar
• KeoghKAYtterbergSRFervenzaFCCarlsonKASchroederDRSpecksURituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trialAm J Respir Crit Care Med2006173218018716224107
   PubMed Web of Science ®Google Scholar
• KeoghKAWylamMEStoneJHSpecksUInduction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheumatol2005521262268
   PubMedGoogle Scholar
• KallenbergCGHauserTB-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitisNephrol Dial Transplant201530Suppl 1i119i12225753806
   PubMedGoogle Scholar
• SpecksUPro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Nephrol Dial Transplant20153071083108725999375
   PubMed Web of Science ®Google Scholar
• KronbichlerAJayneDRCon: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Nephrol Dial Transplant20153071075108125999374
   PubMed Web of Science ®Google Scholar
• SpecksUIkleDStoneJHInduction regimens for ANCA-associated vasculitisN Engl J Med2013369191865186624195565
   PubMedGoogle Scholar
• LyonsPARaynerTFTrivediSGenetically distinct subsets within ANCA-associated vasculitisN Engl J Med2012367321422322808956
   PubMed Web of Science ®Google Scholar
• GeethaDSpecksUStoneJHRituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvementJ Am Soc Nephrol201526497698525381429
   PubMed Web of Science ®Google Scholar
• SandersJSHuitmaMGKallenbergCGStegemanCAPrediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatmentRheumatology (Oxford)200645672472916399845
   PubMed Web of Science ®Google Scholar
• StegemanCATervaertJWSluiterWJMansonWLde JongPEKallenbergCGAssociation of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosisAnn Intern Med1994120112178250451
   PubMed Web of Science ®Google Scholar
• BoomsmaMMStegemanCAvan der LeijMJPrediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective studyArthritis Rheumatol200043920252033
   PubMed Web of Science ®Google Scholar
• TomassonGGraysonPCMahrADLavalleyMMerkelPAValue of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysisRheumatology (Oxford)201251110010922039267
   PubMed Web of Science ®Google Scholar
• HendersonSRCopleySJPuseyCDIndPWSalamaADProlonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA)Medicine (Baltimore)20149327e22925501085
   PubMed Web of Science ®Google Scholar
• ShahSHruskovaZSegelmarkMTreatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximabAm J Nephrol2015414–529630126044574
   PubMed Web of Science ®Google Scholar
• LovricSErdbrueggerUKümpersPRituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patientsNephrol Dial Transplant200924117918518685144
   PubMed Web of Science ®Google Scholar
• KhanALawsonCAQuinnMAIsdaleAHGreenMJSuccessful treatment of ANCA-negative Wegener’s granulomatosis with rituximabInt J Rheumatol2010201084606321049001
   PubMedGoogle Scholar
• SmithKGJonesRBBurnsSMJayneDRLong-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatmentArthritis Rheumatol200654929702982
   PubMed Web of Science ®Google Scholar
• SpecksUBiologic therapy in ANCA-associated vasculitis: new perspectiveAnn Rheum Dis201574Suppl 23
   Google Scholar
• de GrootKHarperLJayneDRPulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trialAnn Intern Med20091501067068019451574
   PubMed Web of Science ®Google Scholar
• HarperLMorganMDWalshMPulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-upAnn Rheum Dis201271695596022128076
   PubMed Web of Science ®Google Scholar
• WalshMFlossmannOBerdenARisk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheumatol2012642542548
   PubMed Web of Science ®Google Scholar
• JonesRBFurutaSTervaertJWRituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trialAnn Rheum Dis20157461178118225739829
   PubMed Web of Science ®Google Scholar
• JayneDRasmussenNAndrassyKA randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodiesN Engl J Med20033491364412840090
   PubMed Web of Science ®Google Scholar
• GuillevinLPagnouxCKarrasARituximab versus azathioprine for maintenance in ANCA-associated vasculitisN Engl J Med2014371191771178025372085
   PubMed Web of Science ®Google Scholar
• HellmichBFlossmannOGrossWLEULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnn Rheum Dis200766560561717170053
   PubMed Web of Science ®Google Scholar
• SmithRMJonesRBGuerryMJRituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheumatol2012641137603769
   PubMedGoogle Scholar
• PendergraftWF3rdCortazarFBWengerJLong-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitisClin J Am Soc Nephrol20149473674424626432
   PubMed Web of Science ®Google Scholar
• McGregorJGHoganSLHuYJennetteCEFalkRJNachmanPHGlucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody diseaseClin J Am Soc Nephrol20127224024722134625
   PubMed Web of Science ®Google Scholar
• WalshMMerkelPAMahrAJayneDEffects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysisArthritis Care Res201062811661173
   PubMed Web of Science ®Google Scholar
• AzarLSpringerJLangfordCAHoffmanGSRituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener’s): a retrospective single-center studyArthritis Rheumatol201466102862287024943239
   PubMed Web of Science ®Google Scholar
• BesadaEKoldingsnesWNossentJCSerum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitisRheumatology (Oxford)201453101818182424831059
   PubMed Web of Science ®Google Scholar
• MarcoHSmithRMJonesRBThe effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune diseaseBMC Musculoskelet Disord20141517824884562
   PubMed Web of Science ®Google Scholar
• VenhoffNEffelsbergNMSalzerUImpact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitidesPloS One201275e3762622629432
   PubMed Web of Science ®Google Scholar
• RobertsDMJonesRBSmithRMImmunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case seriesJ Autoimmun201557242925586449
   PubMed Web of Science ®Google Scholar